Rethinking Melatonin Dosing: Safety and Efficacy at Higher-than-Usual Levels in Aged Patients with Sleep Disturbances and Comorbidities

Background. Although melatonin is widely used in Sleep Medicine for its chronobiological action, its potent antioxidant and mitochondrial regulatory effects, as well as its immunomodulatory and anti-inflammatory functions, make it of interest as a cytoprotective agent in several chronic pathologies....

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Valiensi, Stella M., Vera, Vanesa A., Folgueira, Agustín L., Caporale, Sofía, Ponce de León, Marcela, Pino Fernández, Isis, Vigo, Daniel E., Cardinali, Daniel P.
Formato: Artículo
Lenguaje:Inglés
Publicado: MDPI 2025
Materias:
HIPERTENSION ARTERIAL
CARDIOPATIAS
MELATONINA
SUEÑO
DIABETES
Acceso en línea:https://repositorio.uca.edu.ar/handle/123456789/20651
Aporte de:
Repositorio Institucional de la Universidad Católica Argentina (UCA) de Universidad Católica Argentina
id I33-R139-123456789-20651
record_format dspace
spelling I33-R139-123456789-206512025-09-30T05:01:54Z Rethinking Melatonin Dosing: Safety and Efficacy at Higher-than-Usual Levels in Aged Patients with Sleep Disturbances and Comorbidities Valiensi, Stella M. Vera, Vanesa A. Folgueira, Agustín L. Caporale, Sofía Ponce de León, Marcela Pino Fernández, Isis Vigo, Daniel E. Cardinali, Daniel P. HIPERTENSION ARTERIAL CARDIOPATIAS MELATONINA SUEÑO DIABETES Background. Although melatonin is widely used in Sleep Medicine for its chronobiological action, its potent antioxidant and mitochondrial regulatory effects, as well as its immunomodulatory and anti-inflammatory functions, make it of interest as a cytoprotective agent in several chronic pathologies. These actions are evident at doses higher than those used for sleep disorders. Even at high doses, melatonin’s adverse effects are few, mild, and self-limited or resolve quickly after discontinuation of treatment. Based on its safety profile, we treated melatonin for sleep disorders in the presence of comorbidities with doses ≥ 40 mg daily. Methods. This was a retrospective mixed observational analytical design comprising a retrospective uncontrolled cohort analysis and a cross-sectional study. Eighty-one patients (57 female) with sleep disorders ranging in age from 55 to 98 years (mean 74.4 years) were treated with melatonin 40 to 200 mg daily (mean 72.7 mg) were examined. Fifty-six percent of patients received treatment for more than 4 years. The control group for the cross-sectional analysis included 81 patients over 52 years of age, matched by age and sex and not receiving melatonin but having sleep disorders within the same period. Results. A significant decrease was observed in arterial hypertension, ischemic heart disease and diabetes mellitus after melatonin administration. Analysis of clinical laboratory variables indicated no changes in the treated group versus the untreated group, except for a lower alkaline phosphatase concentration in patients who received melatonin. Conclusions. These findings suggest a beneficial effect of cytoprotective doses of melatonin on the cardiovascular and metabolic profile in an aged population. 2025-09-29T20:58:20Z 2025-09-29T20:58:20Z 2025 Artículo 2076-3425 https://repositorio.uca.edu.ar/handle/123456789/20651 10.3390/ brainsci15101040 eng Atribución-NoComercial-CompartirIgual 4.0 Internacional http://creativecommons.org/licenses/by-nc-sa/4.0/ application/pdf MDPI Brain Sci. 15(1040), 2025
institution Universidad Católica Argentina
institution_str I-33
repository_str R-139
collection Repositorio Institucional de la Universidad Católica Argentina (UCA)
language Inglés
topic HIPERTENSION ARTERIAL
CARDIOPATIAS
MELATONINA
SUEÑO
DIABETES
spellingShingle HIPERTENSION ARTERIAL
CARDIOPATIAS
MELATONINA
SUEÑO
DIABETES
Valiensi, Stella M.
Vera, Vanesa A.
Folgueira, Agustín L.
Caporale, Sofía
Ponce de León, Marcela
Pino Fernández, Isis
Vigo, Daniel E.
Cardinali, Daniel P.
Rethinking Melatonin Dosing: Safety and Efficacy at Higher-than-Usual Levels in Aged Patients with Sleep Disturbances and Comorbidities
topic_facet HIPERTENSION ARTERIAL
CARDIOPATIAS
MELATONINA
SUEÑO
DIABETES
description Background. Although melatonin is widely used in Sleep Medicine for its chronobiological action, its potent antioxidant and mitochondrial regulatory effects, as well as its immunomodulatory and anti-inflammatory functions, make it of interest as a cytoprotective agent in several chronic pathologies. These actions are evident at doses higher than those used for sleep disorders. Even at high doses, melatonin’s adverse effects are few, mild, and self-limited or resolve quickly after discontinuation of treatment. Based on its safety profile, we treated melatonin for sleep disorders in the presence of comorbidities with doses ≥ 40 mg daily. Methods. This was a retrospective mixed observational analytical design comprising a retrospective uncontrolled cohort analysis and a cross-sectional study. Eighty-one patients (57 female) with sleep disorders ranging in age from 55 to 98 years (mean 74.4 years) were treated with melatonin 40 to 200 mg daily (mean 72.7 mg) were examined. Fifty-six percent of patients received treatment for more than 4 years. The control group for the cross-sectional analysis included 81 patients over 52 years of age, matched by age and sex and not receiving melatonin but having sleep disorders within the same period. Results. A significant decrease was observed in arterial hypertension, ischemic heart disease and diabetes mellitus after melatonin administration. Analysis of clinical laboratory variables indicated no changes in the treated group versus the untreated group, except for a lower alkaline phosphatase concentration in patients who received melatonin. Conclusions. These findings suggest a beneficial effect of cytoprotective doses of melatonin on the cardiovascular and metabolic profile in an aged population.
format Artículo
author Valiensi, Stella M.
Vera, Vanesa A.
Folgueira, Agustín L.
Caporale, Sofía
Ponce de León, Marcela
Pino Fernández, Isis
Vigo, Daniel E.
Cardinali, Daniel P.
author_facet Valiensi, Stella M.
Vera, Vanesa A.
Folgueira, Agustín L.
Caporale, Sofía
Ponce de León, Marcela
Pino Fernández, Isis
Vigo, Daniel E.
Cardinali, Daniel P.
author_sort Valiensi, Stella M.
title Rethinking Melatonin Dosing: Safety and Efficacy at Higher-than-Usual Levels in Aged Patients with Sleep Disturbances and Comorbidities
title_short Rethinking Melatonin Dosing: Safety and Efficacy at Higher-than-Usual Levels in Aged Patients with Sleep Disturbances and Comorbidities
title_full Rethinking Melatonin Dosing: Safety and Efficacy at Higher-than-Usual Levels in Aged Patients with Sleep Disturbances and Comorbidities
title_fullStr Rethinking Melatonin Dosing: Safety and Efficacy at Higher-than-Usual Levels in Aged Patients with Sleep Disturbances and Comorbidities
title_full_unstemmed Rethinking Melatonin Dosing: Safety and Efficacy at Higher-than-Usual Levels in Aged Patients with Sleep Disturbances and Comorbidities
title_sort rethinking melatonin dosing: safety and efficacy at higher-than-usual levels in aged patients with sleep disturbances and comorbidities
publisher MDPI
publishDate 2025
url https://repositorio.uca.edu.ar/handle/123456789/20651
work_keys_str_mv AT valiensistellam rethinkingmelatonindosingsafetyandefficacyathigherthanusuallevelsinagedpatientswithsleepdisturbancesandcomorbidities
AT veravanesaa rethinkingmelatonindosingsafetyandefficacyathigherthanusuallevelsinagedpatientswithsleepdisturbancesandcomorbidities
AT folgueiraagustinl rethinkingmelatonindosingsafetyandefficacyathigherthanusuallevelsinagedpatientswithsleepdisturbancesandcomorbidities
AT caporalesofia rethinkingmelatonindosingsafetyandefficacyathigherthanusuallevelsinagedpatientswithsleepdisturbancesandcomorbidities
AT poncedeleonmarcela rethinkingmelatonindosingsafetyandefficacyathigherthanusuallevelsinagedpatientswithsleepdisturbancesandcomorbidities
AT pinofernandezisis rethinkingmelatonindosingsafetyandefficacyathigherthanusuallevelsinagedpatientswithsleepdisturbancesandcomorbidities
AT vigodaniele rethinkingmelatonindosingsafetyandefficacyathigherthanusuallevelsinagedpatientswithsleepdisturbancesandcomorbidities
AT cardinalidanielp rethinkingmelatonindosingsafetyandefficacyathigherthanusuallevelsinagedpatientswithsleepdisturbancesandcomorbidities
_version_ 1845298079989760000

Ejemplares similares